NWBO

Northwest Biotherapeutics, Inc. Press Releases

$6.17
*  
0.01
0.16%
Get NWBO Alerts
*Delayed - data as of Aug. 22, 2014 12:28 ET  -  Find a broker to begin trading NWBO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    NWBO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING
8/19/2014 2:44:00 PM - PR Newswire

NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
8/14/2014 11:47:00 AM - PR Newswire

NW BIO CORRECTS ONGOING FALSE CLAIMS BY FEUERSTEIN ABOUT PHASE III TRIAL OF DCVAX®-L, AND INTERIM ANALYSIS
8/13/2014 9:26:00 AM - PR Newswire

NW BIO PROVIDES UPDATE ABOUT PHASE III DCVAX®-L TRIAL FOR GBM AND "INFORMATION ARM" COMPASSIONATE USE PATIENTS
8/11/2014 8:15:00 AM - PR Newswire

NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER
8/11/2014 8:15:00 AM - PR Newswire

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire

Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Northwest Biotherapeutics, Inc. Stockholders
7/23/2014 7:13:00 PM - Business Wire

NW BIO ANNOUNCES COMPLETION OF DCVAX®-DIRECT PHASE I TRIAL RECRUITMENT
7/16/2014 8:15:00 AM - PR Newswire

INVESTOR ALERT – Andrews & Springer LLC Is Investigating Northwest Biotherapeutics, Inc. For Possible Violations of Securities Laws - NWBO
7/9/2014 8:00:00 AM - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO
7/7/2014 6:31:00 PM - PR Newswire

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Northwest Biotherapeutics, Inc. (NWBO) To Contact The Firm
7/4/2014 1:17:00 PM - PR Newswire

Robbins Arroyo LLP Is Investigating the Officers and Directors of Northwest Biotherapeutics, Inc. on Behalf of Shareholders
7/1/2014 1:33:00 PM - PR Newswire

Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
6/27/2014 7:00:00 AM - PR Newswire

NW BIO REAFFIRMS DCVAX®-DIRECT CLINICAL TRIAL INTERIM DATA ANNOUNCEMENTS
6/20/2014 8:25:00 AM - PR Newswire

Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC
6/19/2014 2:11:00 PM - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO
6/19/2014 11:16:00 AM - PR Newswire

NW BIO NAMED TO TWO RUSSELL INDEXES
6/16/2014 8:15:00 AM - PR Newswire

DCVAX-DIRECT TRIAL UPDATE INDICATES FURTHER POSITIVE RESPONSES; 3 CASE STUDIES SHOW NO LIVE TUMOR CELLS IN INJECTED TUMORS
6/11/2014 8:15:00 AM - PR Newswire

DCVAX®-L PHASE III TRIAL INITIATED IN GERMANY
6/10/2014 8:15:00 AM - PR Newswire

NW BIO TO PRESENT AT JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE
6/4/2014 11:23:00 AM - PR Newswire

NW BIO REFUTES MORE FALSE CLAIMS BY FEUERSTEIN
5/29/2014 9:27:00 AM - PR Newswire

NW BIO TO HOLD CONFERENCE CALL TO DISCUSS EARLY RESULTS OF DCVAX®-DIRECT ONGOING PHASE I/II TRIAL
5/27/2014 12:05:00 PM - PR Newswire

EARLY POSITIVE RESPONSES SEEN IN OVER 50% OF DCVAX®-DIRECT PATIENTS TO DATE
5/27/2014 8:30:00 AM - PR Newswire